Axicabtagene ciloleucel regulatory update

Kite began submission of a rolling BLA to FDA for axicabtagene ciloleucel to treat relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL) in patients who are ineligible for autologous s...